南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

P2RY13阳性肿瘤相关巨噬细胞促进中性粒细胞凋亡(NETosis),并与多种癌症的不良预后相关。

P2RY13-Negative Tumor-Associated Macrophages Promote NETosis and Are Associated with Poor Prognosis Across Multiple Cancers

Shen Yang, Guangsheng Zhu, Zixuan Hu, Mingbiao Li, Jianfang Wang, Zhanrui Zhang, Jun Chen, Renwang Liu

Journal:Cancers

IF:4.8

DOI:10.3390/cancers18152500

PMID:

Published:2026-08-04

research field:分子生物学药理学细胞生物学肝病学

Abstract

Simple SummaryNeutrophil extracellular traps (NETs) promote tumor progression, yet the mechanisms underlying NET formation (NETosis) within the tumor immune microenvironment remain incompletely understood. Low P2RY13 expression has been linked to pro-tumor neutrophils in lung adenocarcinoma. In this study, pan-cancer bioinformatics analyses showed that reduced P2RY13 expression is commonly associated with poor prognosis. Single-cell and tissue microarray analyses further suggested that P2RY13-negative tumor-associated macrophages (TAMs) are highly enriched in tumor tissues in multiple cancers, including lung adenocarcinoma, liver hepatocellular carcinoma, and colorectal cancer. Increased infiltration of these TAMs was associated with enhanced NET formation. In vitro experiments further confirmed that P2RY13-silenced TAM-like macrophages induce neutrophil NETosis. These findings suggest a potential mechanism by which P2RY13-negative TAMs promote NET formation and contribute to adverse clinical outcomes, providing potential therapeutic insights.Background: Neutrophil extracellular traps (NETs) promote tumor progression and immune evasion across multiple cancers. However, the mechanisms governing NET formation (NETosis) within the tumor immune microenvironment remain incompletely understood. Low P2RY13 expression is associated with the pro-tumor activity of neutrophils in lung adenocarcinoma.Methods: Pan-cancer bioinformatics analyses were performed, including differential gene expression, prognostic, tumor-infiltrating immune cell, and NET scoring analyses. Single-cell profiling was conducted using the Tumor Immune Single-cell Hub 2 database. Immunohistochemical (IHC) and multiplex immunofluorescence (mIF) staining of tissue microarrays (TMAs) was performed to validate findings in lung adenocarcinoma (LUAD), liver hepatocellular carcinoma (LIHC), and colorectal cancer (CRC). In vitro validation was conducted using gene modulation, tumor-cell-conditioned medium (CM) e

本文使用的Yeasen产品

产品应用
购物车
客服
转染试用